Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Shares to List on NYSE

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it intends to transfer its stock from the American Stock Exchange to the New York Stock Exchange on or around Oct. 24.
The firm’s Class A common stock will continue to trade under the ticker BIO, and its Class B common stock will continue to trade under the ticker BIOb.
Bio-Rad President and CEO Norman Schwartz said in a statement that the firm’s shareholders “will benefit from the NYSE’s brand, reputation, and trading efficiencies.”

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.